Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Denosumab or zoledronic acid for bone disease in multiple myeloma

Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece

Denosumab or zoledronic acid for bone disease in multiple myeloma ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )

Extended followup indicates daratumumab with bortezomib and dexamethasone for...

Prof Katja Weisel - University of Tübingen, Tübingen, Germany

Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )

Enasidenib in mIDH relapsed and refractory AML

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA

$Enasidenib in mIDH relapsed and refractory AML ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )$

Impact of mutational profile at diagnosis for MDS/CML

Dr Guillermo Montalban Bravo - MD Anderson Cancer Center, Houston, USA

Triplet therapy for all comers in the CLL-BAG trial

Dr Paula Cramer – University of Cologne, Cologne, Germany

Triplet therapy for all comers in the CLL-BAG trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )

Disruption of BAFF-BCR crosstalk in CLL

Dr Alexey Danilov - Knight Cancer Institute, Portland, USA

Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )

Blood thinners a risk with cancer-associated venous thromboembolism

Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London...

Blood thinners a risk with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma

Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma ( Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany )

ZUMA 1: CD19 CAR T cells for refractory NHL

Dr Yi Lin, Mayo Clinic - Rochester, MN, USA

$ZUMA 1: CD19 CAR T cells for refractory NHL ( Dr Yi Lin, Mayo Clinic - Rochester, MN, USA )$

Risk and benefit of anti-coagulants for elderly patients with cancer-associated...

Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London...

Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )

400mg imatinib as good as 800mg for 10 year CML survival

Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany

400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )

Carfilzomib combinations in ENDEAVOR and FORTE

Prof Katja Weisel - University of Tübingen, Tübingen, Germany

Carfilzomib combinations in ENDEAVOR and FORTE ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )

More from ecancer